Aktis Oncology Inc (AKTS)

May 25, 2026

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance

May 25, 2026

May 22, 2026

Top Premarket Gainers - Moomoo

May 22, 2026

May 21, 2026

Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang

May 21, 2026

May 21, 2026

Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative

May 21, 2026

May 21, 2026

Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire

May 21, 2026

May 21, 2026

New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan

May 21, 2026

May 18, 2026

Top Cybin (HELP) Competitors 2026 - MarketBeat

May 18, 2026

May 14, 2026

Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan

May 14, 2026

May 13, 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool

May 13, 2026

May 13, 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool

May 13, 2026

May 13, 2026

AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView

May 13, 2026

May 13, 2026

AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView

May 13, 2026

May 13, 2026

Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail

May 13, 2026

May 12, 2026

Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace

May 12, 2026

May 12, 2026

William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo

May 12, 2026

May 11, 2026

TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo

May 11, 2026

May 11, 2026

Aktis: Q1 Earnings Snapshot - 10TV

May 11, 2026

May 11, 2026

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times

May 11, 2026

May 11, 2026

Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView

May 11, 2026

May 11, 2026

Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan

May 11, 2026

May 11, 2026

Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 11, 2026

May 11, 2026

Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan

May 11, 2026

May 11, 2026

Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo

May 11, 2026

May 11, 2026

Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan

May 11, 2026

May 06, 2026

Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire

May 06, 2026

May 06, 2026

Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India

May 06, 2026

May 05, 2026

William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo

May 05, 2026

May 05, 2026

AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView

May 05, 2026

May 05, 2026

Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com Australia

May 05, 2026

May 04, 2026

Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan

May 04, 2026

May 04, 2026

Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire

May 04, 2026

May 04, 2026

Aktis Oncology starts Phase 1b trial of AKY-2519 for advanced prostate cancer targeting B7-H3 tumors - Pluang

May 04, 2026

May 03, 2026

UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan

May 03, 2026

May 03, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

May 03, 2026

Apr 30, 2026

This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Sahm

Apr 30, 2026

Apr 29, 2026

William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $32 - Moomoo

Apr 29, 2026

Apr 29, 2026

William Blair Initiates Aktis Oncology at Outperform - Moomoo

Apr 29, 2026

Apr 28, 2026

Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS) - Seeking Alpha

Apr 28, 2026

Apr 28, 2026

Massachusetts biotech IPOs surge after years of drought - The Business Journals

Apr 28, 2026

Apr 26, 2026

Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance

Apr 26, 2026

Apr 26, 2026

Aktis Oncology prices IPO at $18 per share - MSN

Apr 26, 2026

Apr 24, 2026

Economics Weekly: Capacity Growth—It’s Different This Time - William Blair

Apr 24, 2026

Apr 23, 2026

Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Intuitive Surgical (ISRG) - The Globe and Mail

Apr 23, 2026

Apr 22, 2026

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 22, 2026

Apr 21, 2026

Aktis Oncology to Present Clinical Data on AKY-2519 Targeting B7-H3 at 2026 ASCO Annual Meeting - Quiver Quantitative

Apr 21, 2026

Apr 21, 2026

Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan

Apr 21, 2026

Apr 18, 2026

Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 18, 2026

Apr 17, 2026

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Yahoo Finance

Apr 17, 2026

Apr 17, 2026

Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com - Investing.com India

Apr 17, 2026

Apr 17, 2026

Should I buy Aktis Oncology, Inc. (AKTS) - Zacks Investment Research

Apr 17, 2026